Bodey G P
Am J Med. 1984 Apr;76(4):678-84. doi: 10.1016/0002-9343(84)90294-8.
Protected environments and prophylactic antibiotics have been evaluated as a method for reducing the risk of infection in patients undergoing cancer chemotherapy. Initial studies were conducted in patients with acute leukemia, and most of them demonstrated that patients in the protected environment/prophylactic antibiotic program had fewer infections and infectious deaths than control patients. In two studies, remission rates were significantly higher for the group in the protected environment/prophylactic antibiotic program. Subsequently, studies were conducted in patients with lymphoma, sarcoma, and breast carcinoma. The protected environment/prophylactic antibiotic program reduced the risk of infection and permitted the administration of higher doses of chemotherapy. However, the more intensive chemotherapy only minimally improved response rates or durations of response. Further studies should be directed toward identifying those patients most likely to benefit from this prophylactic program.
已对保护环境和预防性使用抗生素作为降低癌症化疗患者感染风险的一种方法进行了评估。最初的研究是在急性白血病患者中进行的，大多数研究表明，处于保护环境/预防性使用抗生素方案中的患者比对照患者感染及感染相关死亡更少。在两项研究中，处于保护环境/预防性使用抗生素方案组的缓解率显著更高。随后，对淋巴瘤、肉瘤和乳腺癌患者进行了研究。保护环境/预防性使用抗生素方案降低了感染风险，并允许给予更高剂量的化疗。然而，更强的化疗仅略微提高了缓解率或缓解持续时间。进一步的研究应致力于确定那些最有可能从此预防性方案中获益的患者。
